New combo treatment shows promise for inoperable liver cancer
NCT ID NCT05532319
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new treatment for people with liver cancer that cannot be removed by surgery. The treatment combines chemotherapy delivered directly to the liver, a procedure to block the tumor's blood supply, and two drugs (lenvatinib and tislelizumab). The goal was to see if this combination could help control the cancer and improve survival. The study involved 64 participants and has been completed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, 530021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- A new test could reveal how radiation affects the liver
- Ancient wisdom meets modern oncology: can TCM body types forecast treatment side effects?
- Can an epidural pump beat IV painkillers after liver surgery?
- Could a two-vein embolization trick turn inoperable liver tumors into operable ones?
- Could MRI replace CT for sharper cancer radiation planning?